Long-term efficacy of subcutaneous sumatriptan using a novel self-injector

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Migraine is a debilitating neurological condition requiring effective acute treatments.
• Subcutaneous sumatriptan is an established migraine therapy.
• Novel drug delivery systems aim to improve patient convenience and treatment efficacy.

Purpose of the Study:

• To evaluate the long-term efficacy, tolerability, and patient acceptability of subcutaneous sumatriptan 6 mg using a novel self-injector for acute migraine treatment.
• To assess the usability and patient satisfaction with the cartridge system self-injector over a 6-month period.

Main Methods:

• An open, multicenter study involving 80 patients treating all migraine attacks at home for 6 months.
• Patients self-injected subcutaneous sumatriptan 6 mg, with an option for a second injection or rescue medication.
• Primary endpoint: headache improvement from moderate/severe to mild/absent 1 hour after the first injection.

Main Results:

• Headache relief was achieved in a mean of 78% of attacks within 1 hour of the first injection.
• A second injection was needed in 40% of attacks, with 77% achieving relief after the second dose.
• 87% of patients expressed willingness to use the medication again, and over 80% found the injector easy to use.

Conclusions:

• Subcutaneous sumatriptan 6 mg administered via a novel self-injector is an effective and well-tolerated long-term acute treatment for migraine.
• The self-injector system demonstrated high patient acceptability and ease of use, supporting its role in home-based migraine management.